Commercial Products

 

Vernalis Therapeutics, Inc. launched its first product in the US prescription market, Tuzistra® XR (codeine polistirex and chlorpheniramine polistirex) an extended-release CIII cough cold liquid.  The Company also acquired the US rights to Moxatag®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older. 

Click here for full Prescribing Information for Tuzistra® XR, including Boxed Warning and here for the Medication Guide.

Click here for full Prescribing Information for Moxatag®.

Click here for more information on our pipeline.

 

 

 

 

 

Latest News

AGM Statement

Vernalis plc ("Vernalis" or the "Company") provides an update ahead of its Annual General Meeting ("AGM") being held today at 10.30 am at the offices of Covington & Burling, 265 Strand, London WC2R 1BH.

Read more ...

Fact Sheet

For more information on Vernalis, click below to download a copy of our fact sheet

 

Factsheet-Nov14

 

 

 

 

Contact Vernalis Therapeutics

T: 1-484-913-0700
F: 1-610-651 5976

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch